BRIEF published on 12/16/2025 at 21:23, 6 months 7 days ago ABIONYX Pharma Announces a Capital Increase Fundraising Capital Increase Biopharmaceutical ABIONYX Pharma Sepsis
PRESS RELEASE published on 12/16/2025 at 21:18, 6 months 7 days ago Inside Information / Other news releases ABIONYX Pharma launches €1.8m capital increase with removal of preferential subscription rights, subscription price at 3.10 euros for new shares, extending financial visibility until 2026 Capital Increase Biopharma Preferential Subscription Rights ABIONYX Pharma Financial Visibility
PRESS RELEASE published on 12/16/2025 at 21:18, 6 months 7 days ago Informations privilégiées / Autres communiqués ABIONYX Pharma lance une augmentation de capital de 1,8M€ avec suppression du droit préférentiel de souscription à 3,10 euros par action et extension de la visibilité jusqu'à fin 2026 Augmentation De Capital Droit Préférentiel De Souscription ABIONYX Pharma Visibilité 3,10 Euros
BRIEF published on 12/05/2025 at 18:05, 6 months 18 days ago ABIONYX Reports Monthly Voting Rights and Share Data Euronext Paris Share Capital Voting Rights AMF Regulations ABIONYX Pharma
BRIEF published on 12/05/2025 at 18:05, 6 months 18 days ago ABIONYX publie des données mensuelles sur les droits de vote et les actions Euronext Paris Capital Social Droit De Vote ABIONYX Pharma Règlementation De L'AMF
PRESS RELEASE published on 12/05/2025 at 18:00, 6 months 18 days ago Inside Information / Other news releases ABIONYX Pharma discloses monthly statement of total voting rights and shares as per French regulations. Company focused on innovative medicines in rare diseases Shares French Regulations Total Voting Rights ABIONYX Pharma Innovative Medicines
BRIEF published on 11/25/2025 at 18:38, 6 months 28 days ago ABIONYX Pharma Releases Q3 2025 Business Update Revenue Financial Update ABIONYX Pharma Q3 2025 Sepsis Research
BRIEF published on 11/25/2025 at 18:38, 6 months 28 days ago ABIONYX Pharma publie ses prévisions d'activité pour le troisième trimestre 2025 Mise À Jour Financière Revenu ABIONYX Pharma 3e Trimestre 2025 Recherche Sur La Septicémie
PRESS RELEASE published on 11/25/2025 at 18:33, 6 months 28 days ago Inside Information / Other news releases ABIONYX Pharma reports €3.06 million revenue and €2.8 million cash position as of Q3 2025. Expands focus on sepsis and rare diseases Revenue Cash Position ABIONYX Pharma Sepsis Q3 2025
PRESS RELEASE published on 11/25/2025 at 18:33, 6 months 28 days ago Informations privilégiées / Autres communiqués ABIONYX Pharma communique sur son activité et sa trésorerie du 3ème trimestre 2025. Chiffre d’affaires consolidé de 3,06 M€ et trésorerie de 2,8 M€ au 30 septembre 2025 Chiffre D’affaires Biopharmaceutique Trésorerie ABIONYX Pharma Trimestre 2025
Published on 06/24/2026 at 13:05, 48 minutes ago Faraday Copper Reports Drill Results Including Near-Surface Copper Mineralization in the American Eagle Area
Published on 06/24/2026 at 13:00, 53 minutes ago Aston Bay Provides Update on the Storm Copper Project - Advancing Towards Development
Published on 06/24/2026 at 10:12, 3 hours 41 minutes ago Silver Range Expands Alamo Gold-Copper Target
Published on 06/24/2026 at 03:15, 10 hours 38 minutes ago Noram Lithium Adopts Semi-Annual Financial Reporting
Published on 06/24/2026 at 00:00, 13 hours 53 minutes ago Onco-Innovations Engages Nanosoft Polymers to Advance Polymer and Drug Delivery Development for ONC010
Published on 06/24/2026 at 13:00, 53 minutes ago Nebius AI Cloud 3.6 strengthens developer experience and governance for production operations
Published on 06/24/2026 at 12:58, 54 minutes ago EQS-Adhoc: init innovation in traffic systems SE successfully completes cash capital increase through accelerated bookbuilding
Published on 06/24/2026 at 12:50, 1 hour 2 minutes ago Power World Live from Munich: The Next Generation of Carbon-Neutral Heating Infrastructure
Published on 06/24/2026 at 12:48, 1 hour 4 minutes ago NFON AG AGM 2026: Improved profitability and progress in AI growth areas characterise FY 2025
Published on 06/24/2026 at 12:40, 1 hour 12 minutes ago Risen Energy Showcases Full-Scenario Innovations at Intersolar Europe 2026
Published on 06/24/2026 at 09:30, 4 hours 23 minutes ago CP HOPENING - Le 1er Baromètre “Libéralités - Grande Transmission”
Published on 06/23/2026 at 19:47, 18 hours 5 minutes ago GROUPE SFPI: reorganisation de la Direction Générale
Published on 06/23/2026 at 19:47, 18 hours 5 minutes ago GROUPE SFPI: General management reorganisation
Published on 06/23/2026 at 19:10, 18 hours 42 minutes ago GUILLEMOT CORPORATION > EVOLUTION DE LA GOUVERNANCE A COMPTER DU 23 JUIN 2026
Published on 06/23/2026 at 19:10, 18 hours 42 minutes ago GUILLEMOT CORPORATION: Changes to Corporate Governance Effective June 23, 2026
